Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
Moodys
Merck
Express Scripts

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RISPERDAL

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Risperdal

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000374 Treatment for First-Episode Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 Treatment for First-Episode Schizophrenia Completed The Zucker Hillside Hospital Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00000374 Treatment for First-Episode Schizophrenia Completed Northwell Health Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
NCT00044655 Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00048802 Treatment and Outcome of Early Onset Bipolar Disorder Completed National Institute of Mental Health (NIMH) Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802 Treatment and Outcome of Early Onset Bipolar Disorder Completed Northwell Health Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Risperdal

Condition Name

Condition Name for Risperdal
Intervention Trials
Schizophrenia 55
Schizoaffective Disorder 17
Bipolar Disorder 15
Psychotic Disorders 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Risperdal
Intervention Trials
Schizophrenia 56
Psychotic Disorders 29
Disease 27
Bipolar Disorder 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Risperdal

Trials by Country

Trials by Country for Risperdal
Location Trials
United States 166
Canada 16
India 8
Spain 6
Malaysia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Risperdal
Location Trials
California 17
Texas 11
New York 10
Georgia 10
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Risperdal

Clinical Trial Phase

Clinical Trial Phase for Risperdal
Clinical Trial Phase Trials
Phase 4 39
Phase 3 22
Phase 2 8
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Risperdal
Clinical Trial Phase Trials
Completed 79
Unknown status 4
Not yet recruiting 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Risperdal

Sponsor Name

Sponsor Name for Risperdal
Sponsor Trials
National Institute of Mental Health (NIMH) 14
Janssen, LP 13
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 12
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Risperdal
Sponsor Trials
Industry 81
Other 60
NIH 15
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Moodys
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.